Encompass Health (NYSE:EHC) Releases FY 2024 Earnings Guidance

Encompass Health (NYSE:EHC) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 3.770-4.060 for the period, compared to the consensus EPS estimate of 3.970. The company issued revenue guidance of $5.2 billion-$5.3 billion, compared to the consensus revenue estimate of $5.3 billion.

Encompass Health Price Performance

Shares of NYSE EHC opened at $77.69 on Thursday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.28 and a current ratio of 1.28. The firm has a fifty day moving average of $74.10 and a 200 day moving average of $68.80. The firm has a market cap of $7.78 billion, a PE ratio of 22.39, a PEG ratio of 1.42 and a beta of 0.93. Encompass Health has a one year low of $52.32 and a one year high of $78.11.

Encompass Health (NYSE:EHC) last released its earnings results on Wednesday, February 7th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.12. Encompass Health had a return on equity of 17.69% and a net margin of 7.33%. The business had revenue of $1.25 billion for the quarter, compared to the consensus estimate of $1.24 billion. As a group, research analysts predict that Encompass Health will post 3.96 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Monday, April 1st will be given a $0.15 dividend. The ex-dividend date is Thursday, March 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.77%. Encompass Health’s dividend payout ratio (DPR) is presently 17.29%.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Mizuho lifted their price target on Encompass Health from $77.00 to $82.00 and gave the stock a buy rating in a report on Friday, February 9th. Stephens reaffirmed an overweight rating and set a $85.00 target price on shares of Encompass Health in a research note on Tuesday, January 16th. Royal Bank of Canada reissued an outperform rating and issued a $83.00 price target on shares of Encompass Health in a research note on Friday, February 9th. Barclays started coverage on shares of Encompass Health in a research report on Wednesday, March 6th. They set an overweight rating and a $95.00 price target on the stock. Finally, William Blair reaffirmed an outperform rating on shares of Encompass Health in a research report on Wednesday, February 7th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Encompass Health has an average rating of Buy and a consensus price target of $82.56.

Institutional Trading of Encompass Health

A number of hedge funds and other institutional investors have recently bought and sold shares of EHC. Baupost Group LLC MA boosted its holdings in shares of Encompass Health by 318.9% in the 1st quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company’s stock valued at $213,330,000 after buying an additional 2,283,900 shares in the last quarter. Norges Bank acquired a new position in Encompass Health in the fourth quarter valued at $58,988,000. Holocene Advisors LP increased its position in shares of Encompass Health by 3,070.3% during the second quarter. Holocene Advisors LP now owns 574,171 shares of the company’s stock worth $38,877,000 after purchasing an additional 556,060 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Encompass Health by 379.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 578,349 shares of the company’s stock valued at $38,587,000 after purchasing an additional 457,796 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Encompass Health by 4.7% in the 4th quarter. Vanguard Group Inc. now owns 9,997,034 shares of the company’s stock valued at $667,002,000 after purchasing an additional 450,081 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.